ストックスクリーナーアプリを入手
1.17
13.97%
-0.19
アフターアワーズ：
1.17
前日終値:
$1.36
開ける：
$1.45
24時間の取引高:
315.81K
Relative Volume:
0.67
時価総額：
$85.86M
収益：
-
当期純損益:
$-60.36M
株価収益率:
-0.2663
EPS:
-4.394
ネットキャッシュフロー:
$-15.05M
1週間 パフォーマンス:
-12.03%
1か月 パフォーマンス:
-31.98%
6か月 パフォーマンス:
-71.32%
1年 パフォーマンス:
-68.12%
1日の値動き範囲:
$1.16
$1.4525
1週間の範囲:
$1.16
$1.4525
52週間の値動き範囲:
$1.16
$6.35
Zura Bio Ltd Stock (ZURA) Company Profile
ZURA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.17 | 85.86M | 0 | -60.36M | -15.05M | -4.394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-04 | 開始されました | Leerink Partners | Outperform |
| 2024-09-05 | 開始されました | H.C. Wainwright | Neutral |
| 2024-05-03 | 開始されました | Piper Sandler | Overweight |
| 2023-10-10 | 開始されました | Ladenburg Thalmann | Buy |
| 2023-08-25 | 開始されました | Oppenheimer | Outperform |
| 2023-06-22 | 開始されました | Guggenheim | Buy |
| 2023-06-14 | 開始されました | Chardan Capital Markets | Buy |
| 2023-05-24 | 開始されました | Raymond James | Strong Buy |
すべてを表示
Zura Bio Ltd (ZURA) 最新ニュース
Zura Bio to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance
Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $15.80 - Defense World
Zura Bio Limited (NASDAQ:ZURA) Shares Purchased by SG Americas Securities LLC - Defense World
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - ADVFN
ZURA stock touches 52-week low at $1.44 amid market shifts - Investing.com Nigeria
ZURA stock touches 52-week low at $1.44 amid market shifts By Investing.com - Investing.com South Africa
After losing 43% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain - Simply Wall St
Zura Bio (NASDAQ:ZURA) vs. Aptose Biosciences (NASDAQ:APTO) Critical Contrast - Defense World
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA) - MSN
Cantor Fitzgerald Predicts Zura Bio FY2025 Earnings - MarketBeat
We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth - Yahoo Finance
Barclays PLC Purchases 56,757 Shares of Zura Bio Limited (NASDAQ:ZURA) - Defense World
ZURA stock touches 52-week low at $1.97 amid market shifts - Investing.com Canada
Corporate Overview January 2025 Advancing Dual Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases - Marketscreener.com
Zura Bio Highlights Strategic Goals and Clinical Advances - TipRanks
Barclays PLC Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
State Street Corp Increases Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Reversal Of Fortune For Zura Bio Insiders Who Made A US$1.01m Purchase - Simply Wall St
Zura Bio’s (ZURA) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Zura Bio shares outlook positive as Phase 2 TibuSURE study evaluates key SSc complications - Investing.com India
Zura Bio begins Phase 2 study for systemic sclerosis treatment By Investing.com - Investing.com South Africa
Zura Bio initiates Phase II systemic sclerosis treatment trial - Yahoo Finance
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis - Quantisnow
17,442 Shares in Zura Bio Limited (NASDAQ:ZURA) Acquired by The Manufacturers Life Insurance Company - Defense World
Zura Bio FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
Zura Bio FY2025 EPS Forecast Boosted by Leerink Partnrs - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Zura Bio (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average PT from Analysts - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average Target Price from Analysts - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Update - Defense World
Zura Bio : to Present at the Piper Sandler 36th Annual Healthcare Conference Form 8 K - Marketscreener.com
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Zura Bio to Present at Piper Sandler Healthcare Conference, Showcasing Immunology Pipeline - StockTitan
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - Simply Wall St
HC Wainwright Reaffirms “Neutral” Rating for Zura Bio (NASDAQ:ZURA) - Defense World
HC Wainwright Reaffirms "Neutral" Rating for Zura Bio (NASDAQ:ZURA) - MarketBeat
GREAT POINT PARTNERS LLC Reduces Stake in Zura Bio Ltd - GuruFocus.com
ADAR1 Capital Management, LLC Acquires New Stake in Zura Bio Ltd - GuruFocus.com
Zura Bio advances Phase 2 study for systemic sclerosis treatment - Investing.com
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis - Yahoo Finance
HC Wainwright Has Positive Outlook for Zura Bio Q3 Earnings - MarketBeat
Guggenheim maintains Buy on Zura Bio, target steady at $15 - Investing.com India
Guggenheim maintains Buy on Zura Bio, target steady at $15 By Investing.com - Investing.com UK
Q3 Earnings Forecast for Zura Bio Issued By Leerink Partnrs - MarketBeat
Zura Bio (NASDAQ:ZURA) Stock Rating Upgraded by Leerink Partnrs - Defense World
Piper Sandler sets price target on Zura Bio shares, cites positive trial data - Investing.com
Leerink Partners initiates Zura Bio stock with Outperform rating, $15 target - Investing.com
Zura Bio Ltd (ZURA) 財務データ
収益
当期純利益
現金流量
EPS
Zura Bio Ltd (ZURA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Thiara Parvinder | Director |
Sep 11 '24 |
Sale |
2.70 |
3,800,000 |
10,260,000 |
1,001,633 |
| Sidhu Someit | Director |
Sep 04 '24 |
Sale |
3.87 |
51,728 |
200,187 |
2,085,418 |
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):